Welcome to our dedicated page for Edap Tms news (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on Edap Tms stock.
EDAP TMS SA (NASDAQ: EDAP) delivers innovative therapeutic ultrasound solutions for urological care through its HIFU and lithotripsy technologies. This news hub provides investors and medical professionals with essential updates on the company's advancements in robotic medical devices, regulatory milestones, and global market strategies.
Access real-time announcements including clinical trial results, product approvals, financial disclosures, and strategic partnerships. Our curated collection features press releases about EDAP's three operational divisions: HIFU tumor ablation systems, ESWL stone treatment devices, and distribution of complementary medical technologies.
Stay informed about developments in minimally-invasive treatment solutions that demonstrate EDAP's commitment to advancing urological care. The resource is regularly updated with material events affecting the company's position in the competitive medical devices sector.
Bookmark this page for streamlined access to verified information about EDAP's technological innovations, international expansion efforts, and research collaborations with leading medical institutions.
EDAP TMS has published promising pre-clinical results in the peer-reviewed journal Cancers, showcasing the potential of high intensity focused ultrasound (HIFU) for treating locally advanced pancreatic cancer. The study found that HIFU can induce irreversible tissue necrosis rapidly, highlighting its feasibility under Doppler guidance. This research paves the way for a forthcoming Phase I clinical study, aiming to evaluate the safety and efficacy of HIFU in patients with this challenging cancer type. The overall 5-year survival rate for patients with locally advanced pancreatic adenocarcinoma is under 5%, underscoring the need for innovative treatment options.
EDAP TMS announced notable growth for its Focal One device in the U.S., with installations at five leading healthcare centers, including Brigham and Women’s Hospital and Cedars-Sinai, during Q4 2021.
CEO Marc Oczachowski expressed optimism regarding increased market adoption following a restructuring of U.S. operations.
Ryan Rhodes, CEO of EDAP U.S., highlighted the device's significance in prostate oncology as they enter 2022 with strong momentum.
EDAP TMS SA (Nasdaq: EDAP) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The company will engage in investor 1x1 meetings on November 30. A video replay of the fireside chat will be available on EDAP's website post-event. EDAP TMS is recognized for its innovative robotic energy-based therapies, particularly in the therapeutic ultrasound market, with products like the Focal One® and ExactVu™ aimed at prostate cancer treatment.
EDAP TMS SA reported unaudited financial results for Q3 2021, revealing year-to-date revenue of approximately EUR 30.1 million (USD 35.9 million), a 14.4% increase compared to 2020. Q3 revenue remained flat at EUR 9.4 million (USD 11.1 million), impacted by COVID-19 on capital equipment sales. U.S. HIFU treatment volumes rose 58% year-to-date, highlighting strong adoption by urologists. Despite a strong cash position of EUR 45.4 million (USD 52.6 million), Q3 saw a gross profit margin decline to 38.4% due to reduced sales effects on fixed costs. The company will host a conference call on November 18, 2021.
EDAP TMS SA (Nasdaq: EDAP) announced its plans to release third quarter financial results for the period ended September 30, 2021, after market close on November 17, 2021. The company will host a conference call and webcast on November 18, 2021, at 8:30 AM ET, featuring key executives including the CEO and CFO. This event will discuss the financial results and future outlook.
EDAP is recognized for developing minimally invasive medical devices using ultrasound technology for various medical conditions.
EDAP TMS SA (Nasdaq: EDAP) has announced that the University of Washington Medicine will implement the Focal One® high intensity focused ultrasound (HIFU) technology for prostate cancer treatment at its UW Medical Center location. This partnership aims to enhance prostate cancer management through advanced imaging and targeted treatments. Marc Oczachowski, CEO of EDAP, emphasized the global adoption of their technology. The Focal One system offers precise ablation capabilities while minimizing side effects, indicating a significant advancement in prostate cancer care.
EDAP TMS SA (Nasdaq: EDAP) announced data from studies presented at the AUA 2021 Annual Meeting indicating the superiority of High-Intensity Focused Ultrasound (HIFU) over radical prostatectomy for prostate cancer treatment.
The studies revealed that Focal One technology maintained better erectile function and urinary continence, with a salvage-treatment-free survival rate of 97.5% compared to 90.3% for radical prostatectomy. EDAP's advancements in minimally invasive therapies reinforce its position as a leader in the therapeutic ultrasound market.
EDAP TMS announced participation in two September 2021 investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will be held virtually from September 13-15, with a presentation accessible from September 13 at 7:00 am ET. The Lake Street’s 5th Annual Best Ideas Growth Conference will occur virtually on September 14-15, featuring one-on-one meetings with institutional investors. EDAP TMS specializes in robotic energy-based therapies, including advanced ultrasound technologies for prostate cancer treatment.
EDAP TMS SA reported a revenue increase of 22.5% for the first half of 2021, totaling EUR 20.7 million (USD 24.8 million). Despite strong growth in U.S. HIFU treatment volumes, the HIFU business revenue declined by 15.1% year-over-year. Net income improved to EUR 0.4 million (USD 0.4 million), compared to a net loss of EUR 1.5 million in the prior year. The CMS advisory panel recommended increasing HIFU reimbursement rates significantly for 2022, which could boost future sales. The company maintained a robust cash balance of EUR 45 million (USD 53.3 million) as of June 30, 2021.
EDAP TMS SA (Nasdaq: EDAP) reported preliminary second quarter 2021 revenue of approximately EUR 10.4 million (USD $12.4 million), an 11.8% increase year-over-year, with first half revenue rising 22.5% to EUR 20.7 million (USD $24.8 million). U.S. High-Intensity Focused Ultrasound (HIFU) treatment volumes surged 79% compared to 2020, signaling strong adoption in the market. The company ended the quarter with cash and cash equivalents of EUR 45 million (USD $53.3 million) and announced the appointment of Ryan Rhodes as CEO of its U.S. subsidiary. A detailed financial report is expected on August 25, 2021.
FAQ
What is the current stock price of Edap Tms (EDAP)?
What is the market cap of Edap Tms (EDAP)?
